@article {2366,
	title = {Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin},
	journal = {Journal of Inorganic Biochemistry},
	volume = {103},
	number = {4},
	year = {2009},
	note = {ISI Document Delivery No.: 429EUTimes Cited: 8Cited Reference Count: 31Bordbar, Abdol-Khalegh Creagh, A. Louise Mohammadi, Fakhrossadat Haynes, Charles A. Orvig, Chris6th International Vanadium SymposiumJUL 17-19, 2008Lisbon, PORTUGALSp. Iss. SI},
	month = {Apr},
	pages = {643-647},
	type = {Proceedings Paper},
	abstract = {Bis(maltolato)oxovanadium(IV) (BMOV), and its ethylmaltol analog, bis(ethymaltolato)oxovanadium(IV) (BEOV), are candidate insulin-enhancing agents for the treatment of type 2 diabetes mellitus; in mid-2008, BEOV advanced to phase 11 clinical testing. The interactions of BMOV and its inorganic congener, vanadyl Sulfate (VOSO4), with human serum apo-transferrin (hTf) were investigated using differential scanning calorimetry (DSC). Addition of BMOV or VOSO4 to apo-hTf resulted in an increase in thermal stability of both the C- and N-lobes of transferrin as a result of binding to either vanadyl compound. A series of DSC thermograms of hTf Solutions containing different molar ratios of BMOV and VOSO4 were used to determine binding constants: at 25 degrees C the binding constants of BMOV to the C- and N-lobes of apo-hTf were found to be 3 (+/- 1) x 10(5) and 1.8 (+/- 0.7) x 10(5) M-1, respectively. The cot-responding values for VOSO4 were 1.7 (+/- 0.3) x 10(5) and 7 (+/- 2) x 10(4) M-1. The results show that the vanadium species initially presented as either BMOV or VOSO4 had similar affinities for human serum transferrin due to oxidation of solvated vanadyl(IV) prior to complexation to transferrin. Binding of metavanadate (VO3-) was confirmed by DSC and isothermal titration calorimetry (ITC) experiments of the interaction between sodium metavanadate (NaVO3) and hTf. (C) 2008 Elsevier Inc. All rights reserved.},
	keywords = {Apo-transferrin, BINDING, BIS(MALTOLATO)OXOVANADIUM(IV), CHEMISTRY, COMPLEXES, Insulin-enhancing, iron, MALTOL, MOLYBDENUM, NICKEL, RATS, STABILITY, VANADIUM},
	isbn = {0162-0134},
	url = {<Go to ISI>://000264904400022},
	author = {Bordbar, A. K. and Creagh, A. L. and Mohammadi, F. and Haynes, C. A. and Orvig, Chris}
}
@article {2637,
	title = {Vanadium treatment of type 2 diabetes: A view to the future},
	journal = {Journal of Inorganic Biochemistry},
	volume = {103},
	number = {4},
	year = {2009},
	note = {ISI Document Delivery No.: 429EUTimes Cited: 20Cited Reference Count: 41Thompson, Katherine H. Lichter, Jay LeBel, Carl Scaife, Michael C. McNeill, John H. Orvig, Chris6th International Vanadium SymposiumJUL 17-19, 2008Lisbon, PORTUGALSp. Iss. SI},
	month = {Apr},
	pages = {554-558},
	type = {Proceedings Paper},
	abstract = {3-Hydroxy-2-methyl-4-pryone and 2-ethyl 3-hydroxy-4-pyrone (maltol and ethyl maltol, respectively) have proven especially suitable a ligands for vanadyl tons, fit potential insulin enhancing agents for diabetes mellitus. Both bis(maltolato)oxovanadium(IV) (BMOV), and the ethylmaltol analog, bis(ethylmaltolato)oxovanadium(IV) (BEOV), have the desired intermediate stability for pro-drug use, and have undergone extensive pie-clinical testing for safety and efficacy. Pharmacokinetic evaluation indicates a pattern of biodistribution consistent with fairly rapid dissociation and uptake, binding to serum transferrin for systemic circulation and transport to tissues, with preferential uptake in bone. These bis-ligand oxovanadium(IV) (VOL2) compounds have a clear advantage over inorganic vanadyl sulfate in terms of bioavailability and pharmaceutical efficacy. BEOV has now completed Phase I and has advanced to Phase II clinical trials. In the Phase I trial, a ran-e of doses horn 10 mg, to 90 mg BEOV, given orally to non-diabetic volunteers, resulted in no adverse effects, all biochemical parameters remained within normal limits. In the Phase IIa trial, BEOV (AKP-020). 20 mg, daily for 28 clays, per os, in seven type 2 diabetic Subjects, was associated with reductions in fasting blood and glucose and \%HbA1c; improved responses to oral glucose tolerance testing, versus, the observed worsening of diabetic symptoms in the two placebo controls. (C) 2009 Elsevier Inc. All rights reserved.},
	keywords = {BIODISTRIBUTION, bis(ethylmaltolato)oxovanadium(IV), BIS(MALTOLATO)OXOVANADIUM(IV), CHEMISTRY, Diabetes mellitus, IN-VIVO, INSULIN SENSITIVITY, MALTOL, METAL-COMPLEXES, RATS, SERUM, SKELETAL-MUSCLE, SULFATE, VANADIUM},
	isbn = {0162-0134},
	url = {<Go to ISI>://000264904400011},
	author = {Thompson, K. H. and Lichter, J. and Lebel, C. and Scaife, M. C. and McNeill, J. H. and Orvig, Chris}
}
@article {1112,
	title = {Chromatographic separation and identification of products from the reaction of dimethylarsinic acid with hydrogen sulfide},
	journal = {Chemical Research in Toxicology},
	volume = {18},
	number = {12},
	year = {2005},
	note = {ISI Document Delivery No.: 004XYTimes Cited: 24Cited Reference Count: 44},
	month = {Dec},
	pages = {1821-1829},
	type = {Article},
	abstract = {The reaction of dimethylarsinic acid (DMA(V)) with hydrogen sulfide (H2S) is of biological significance and may be implicated in the overall toxicity and carcinogenicity of arsenic. The course of the reaction in aqueous phase was monitored, and an initial product, dimethylthioarsinic acid, was observed by using LC-ICP-MS and LC-ESI-MS. Dimethylarsinous acid was observed as a minor product. A second slower-forming product was identified, and the electrospray mass chromatograms for this species produced ions at m/z 275, 171, and 137 in positive mode. To aid in the identification of this slower-forming product, crystalline standards of sodium dimethyldithioarsinate and dimethylarsino dimethyldithioarsinate were prepared and re-characterized by using improved spectroscopic and structural analysis techniques. An aqueous solution of sodium dimethyldithioarsinate produced a single major chromatographic peak that matched the retention time (7.6 min) of the slower-forming product and contained similar molecular ions at m/z 275, 171, and 137 via LC-ESI-MS. The dimethylarsino dimethyldithioarsinate standard produced four aqueous phase species one of which coeluted with the slower forming product. This coeluting peak also produced the identical ESI-MS ions as the slower-forming product of DMA(V) + H2S. ESI-MS/MS experiments conducted on sodium dimethyldithioarsinate in deuterated water produced molecular ions at m/z 276, 173, and 137. Subsequent collisionally activated dissociation (CAD) experiments on m/z 276 did not produce a product ion at m/z 173. These data indicate that two different species are present in solution, while NMR data indicate that only dimethyldithioarsinic acid exists in aqueous solutions. This discrepancy was investigated by conducting NMR studies on the acidic solution of sodium dimethyldithioarsinate after taking this solution to dryness. The resolubilized solution produced a proton NMR signal characteristic of dimethylarsino dimethyldithioarsinate. Therefore, it was concluded that the ESI-MS ion at m/z 275 associated with the slowly forming second reaction product and the sodium dimethyldithioarsinate compound is a product of the ESI desolvation process.},
	keywords = {CRYSTAL-STRUCTURE, DIMETHYLDITHIOARSINATE, GLUTATHIONE, METABOLITE, ORGANIC ARSENIC COMPOUNDS, RATS, REARRANGEMENT, TOXICITY, TRIMETHYLARSINE OXIDE, urine},
	isbn = {0893-228X},
	url = {<Go to ISI>://000234787200005},
	author = {Fricke, M. W. and Zeller, M. and Sun, H. and Lai, V. W. M. and Cullen, W. R. and Shoemaker, J. A. and Witkowski, M. R. and Creed, J. T.}
}
@article {1011,
	title = {Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes},
	journal = {Journal of Inorganic Biochemistry},
	volume = {98},
	number = {5},
	year = {2004},
	note = {ISI Document Delivery No.: 824HVTimes Cited: 37Cited Reference Count: 7411th International Conference on Biological Inorganic ChemistryJUL 19-23, 2003Cairns, AUSTRALIA},
	month = {May},
	pages = {683-690},
	type = {Proceedings Paper},
	abstract = {A wide variety of vanadium-containing complexes have been tested, both in vivo and in vitro, as possible therapeutic agents for the oral treatment of type 2 diabetes mellitus. None so far has surpassed bis(maltolato)oxovanadium(IV) (BMOV) for glucose- and lipid-lowering in an orally available formulation. Ligand choice is clearly an important factor in pharmacological efficacy of vanadium compounds as insulin enhancing agents. In this study, we kept the ligand and dose the same, varying instead the metal ion bound to the maltolato ligand in a series of binary complexes of neutral charge. A requirement for vanadyl ion as the metal ion of choice was apparent; no other metal ion tested served as a suitable substitute. Amongst [MoO2](2+), Co(II), Cu(II), Cr(III), and Zn(II), only [MoO2](2+) and Co(II) showed any hypoglycemic activity at the ED50 dose for bis(maltolato)oxovanadium(IV), 0.6 mmol kg(-1) by oral gavage in streptozotocin (STZ)-diabetic rats within 72 It of administration of compound. (C) 2004 Elsevier Inc. All rights reserved.},
	keywords = {ABSORPTION, CHROMIUM, cobalt, COORDINATION MODE, copper, DEPENDENT DIABETES-MELLITUS, GLUCOSE-METABOLISM, IN-VIVO, INSULIN, LIPID-METABOLISM, MOLYBDENUM, RATS, VANADIUM, zinc, ZINC SUPPLEMENTATION},
	isbn = {0162-0134},
	url = {<Go to ISI>://000221678300004},
	author = {Thompson, K. H. and Chiles, J. and Yuen, V. G. and Tse, J. and McNeill, J. H. and Orvig, Chris}
}
@article {784,
	title = {Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats},
	journal = {Canadian Journal of Physiology and Pharmacology},
	volume = {81},
	number = {11},
	year = {2003},
	note = {ISI Document Delivery No.: 749AHTimes Cited: 3Cited Reference Count: 47},
	month = {Nov},
	pages = {1049-1055},
	type = {Article},
	abstract = {The aim of this study was to determine if there was a synergistic or additive effect of a thiazolidinedione derivative (rosiglitazone (ROS)) and a vanadium compound (bis(ethylmaltolato)oxovanadium(IV) (BEOV)) on plasma glucose and insulin levels following chronic oral administration to Zucker diabetic fatty (ZDF) rats. Whole-blood vanadium levels were determined at time 0 and at days 1, 6, and 18. The doses of BEOV (0.1 mmol/kg) and ROS (2.8 mumol/kg) were selected to produce a glucose-lowering effect in 30\% (ED30) of animals. Both drugs were administered daily by oral gavage as suspensions in 1\% carboxymethylcellulose (CMC) in a volume of 2.5 mL/kg. The total volume administered to all rats was 5 mL/(kg-day). The combination of BEOV and ROS was effective in lowering plasma glucose levels to <9 mmol/L in 60\% of fatty animals as compared with 30\% for BEOV and 10\% for ROS alone. The age-dependent decrease in plasma insulin levels associated with \&beta;-cell failure in the ZDF rats did not occur in the BEOV-treated fatty groups. There was no effect of any treatment on body weight; however, there was a significant reduction in both food and fluid intake in fatty groups treated with BEOV. There were no overt signs of toxicity and no mortality in this study. Both BEOV and ROS were effective in lowering plasma glucose levels, as stated above, and there was at least an additive effect when BEOV and ROS were used in combination.},
	keywords = {ACTIVATED-RECEPTOR-GAMMA, bis(ethylmaltolato)oxovanadium(IV), diabetes, GLUT4, IN-VIVO, INSULIN SENSITIVITY, ORAL VANADYL, PHOSPHOENOLPYRUVATE-CARBOXYKINASE, RATS, rosigitazone, SKELETAL-MUSCLE, STREPTOZOTOCIN-DIABETIC RATS, TRANSLOCATION, VANADYL SULFATE, ZDF rats, ZUCKER FATTY},
	isbn = {0008-4212},
	url = {<Go to ISI>://000186896100007},
	author = {Yuen, V. G. and Bhanot, S. and Battell, M. L. and Orvig, Chris and McNeill, J. H.}
}
@article {664,
	title = {Demethylation of methylarsenic species by Mycobacterium neoaurum},
	journal = {Applied Organometallic Chemistry},
	volume = {17},
	number = {11},
	year = {2003},
	note = {ISI Document Delivery No.: 737CBTimes Cited: 6Cited Reference Count: 26},
	month = {Nov},
	pages = {831-834},
	type = {Article},
	abstract = {Mycobacterium neoaurum demethylates both methylarsonic acid and methylarsonous acid to mixtures of arsenate and arsenite. After 28 days of incubation, the yields of inorganic arsenic were 27\% from arsenate and 43\% from arsenite. A time study of the demethylation of methylarsonic acid by M. neoaurum showed that demethylation occurs rapidly during the growth and stationary phases of the bacterium, and indicates that MMA(V) is reductively demethylated to arsenite. Copyright (C) 2003 John Wiley Sons, Ltd.},
	keywords = {ACID, arsenic, ARSENICALS, ARSINE, CANDIDA-HUMICOLA, DEGRADATION, demethylation, METABOLITES, methylarsonic acid, methylarsonous acid, MICROORGANISMS, Mycobacterium neoaurum, RATS, REDUCTION, SOIL},
	isbn = {0268-2605},
	url = {<Go to ISI>://000186209800002},
	author = {Lehr, C. R. and Polishchuk, E. and Radoja, U. and Cullen, W. R.}
}
@article {757,
	title = {Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential},
	journal = {Journal of Biological Inorganic Chemistry},
	volume = {8},
	number = {1-2},
	year = {2003},
	note = {ISI Document Delivery No.: 638ACTimes Cited: 62Cited Reference Count: 52},
	month = {Jan},
	pages = {66-74},
	type = {Article},
	abstract = {A series of 2-alkyl-3-hydroxy-4-pyrone oxovanadium(IV) compounds has been synthesized, characterized, and tested for bioactivity as potential insulin-enhancing agents. The vanadyl complexes, bis(maltolato)oxovanadium(IV), BMOV, bis(ethylmaltolato)oxovanadium(IV), BEOV, and bis(isopropylmaltolato) oxovanadium(IV), BIOV, were compared against vanadyl sulfate for glucose-lowering ability, when administered i.p. to STZ-diabetic rats, at a one-time dose of 0.1 mmol kg(-1) body weight. Blood levels of vanadium were determined at regular intervals, to 72 h, following i.p. injection. All complexes tested exceeded vanadyl sulfate in glucose-lowering ability; this effect was not correlated, however, with blood vanadium levels. Analysis of the pharmacokinetics of the disappearance of [ethyl-1-C-14]BEOV after an oral gavage dose (50 mg kg(-1), 0.144 mmol kg(-1), in a 10 mL kg(-1) volume of 1\% CMC solution) indicated clearly that metal ion-ligand dissociation took place relatively soon after oral ingestion of the complex. Half-lives of fast phase uptake and slow phase disappearance for C-14 and V were calculated from a two-compartment model for whole blood, plasma, liver, kidney, bone, small intestine, and lung, ranging from 17 min (t(1/2)alpha for C-14, liver) to 30 days (t(1/2)beta for V, bone). Curves of disappearance of plasma and whole blood C-14 and V diverged dramatically within the first hour after administration of the vanadium complex.},
	keywords = {ABSORPTION, BIS(MALTOLATO)OXOVANADIUM(IV) BMOV, CHEMISTRY, COORDINATION MODE, ETHYL MALTOL, IN-VITRO, INSULIN MIMETIC AGENT, insulin-enhancing activity, pharmacokinetics, PHOSPHATIDYLINOSITOL 3-KINASE, POLYMORPHIC FORMS, RATS, STZ-diabetic rat, vanadyl pyrone complexes},
	isbn = {0949-8257},
	url = {<Go to ISI>://000180545000008},
	author = {Thompson, K. H. and Liboiron, B. D. and Bellman, Yskdd and Setyawati, I. A. and Patrick, B. O. and Karunaratne, V. and Rawji, G. and Wheeler, J. and Sutton, K. and Bhanot, S. and Cassidy, C. and McNeill, J. H. and Yuen, V. G. and Orvig, Chris}
}
@article {546,
	title = {Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour},
	journal = {Neuromolecular Medicine},
	volume = {1},
	number = {3},
	year = {2002},
	note = {ISI Document Delivery No.: 608VHTimes Cited: 38Cited Reference Count: 42},
	pages = {207-221},
	type = {Article},
	abstract = {Consumption of cycad seed products (Cycas circinalis) is one of the strongest epidemiological links to the Guamian neurological disorder amyotrophic lateral sclerosis-parkinsonism-dementia complex (ALS-PDC), however, the putative toxin which causes neurodegeneration has never been identified definitively. To reexamine this issue, 6-7-mo-old, male CD-1 mice were assessed for motor and cognitive behaviours during and following feeding with pellets made from washed cycad flour. Cycad-fed animals showed early evidence of progressive motor and cognitive dysfunctions. Neurodegeneration measured using TUNEL and caspase-3 labeling was found in neocortex, various hippocampal fields, substantia nigra, olfactory bulb, and spinal cord. In vitro studies using rat neocortex have identified toxic compounds in washed cycad flour that induce depolarizing field potentials and lead to release of lactate dehydrogenase (LDH), both blocked by AP5. High-performance liquid chromatography (HPLC)/mass spectrometry of cycad flour samples failed to show appreciable amounts of other known cycad toxins, cycasin, MAM, or BMAA; only trace amounts of BOAA were present. Isolation procedures employing these techniques identified the most toxic component as P-sitosterol beta-D-glucoside (BSSG). The present data suggest that a neurotoxin, or a toxic metabolite, not previously identified in cycad, is able to gain access to central nervous system (CNS) resulting in neurodegeneration of specific neural populations and in motor and cognitive dysfunctions. These data are consistent with a number of major features of ALS-PDC in humans.},
	keywords = {ALS, ALS-PDC, Alzheimer{\textquoteright}s disease, AMYOTROPHIC-LATERAL-SCLEROSIS, BMAA, CORTEX, cycad, dementia, DISEASE, GUAM, HIPPOCAMPUS, MAZE, neurodegeneration, neurotoxicity, NEUROTOXIN, parkinsonism, PERFORMANCE, RATS},
	isbn = {1535-1084},
	url = {<Go to ISI>://000178867500005},
	author = {Wilson, J. M. B. and Khabazian, I. and Wong, M. C. and Seyedalikhani, A. and Bains, J. S. and Pasqualotto, B. A. and Williams, D. E. and Andersen, R. J. and Simpson, R. J. and Smith, R. and Craig, U. K. and Kurland, L. T. and Shaw, C. A.}
}
@article {4706,
	title = {Vanadyl-biguanide complexes as potential synergistic insulin mimics},
	journal = {Journal of Inorganic Biochemistry},
	volume = {76},
	number = {3-4},
	year = {1999},
	note = {ISI Document Delivery No.: 262ZHTimes Cited: 65Cited Reference Count: 27},
	month = {Sep},
	pages = {251-257},
	type = {Article},
	abstract = {Vanadium has well-documented blood-glucose-lowering properties both in vitro and in vivo. The design of new oxovanadium(IV) coordination compounds, intended for use as insulin-enhancing agents in the treatment of diabetes mellitus, can potentially benefit from a synergistic approach, in which the whole complex has more than an additive effect from its component parts. Biguanides, most importantly metformin, are oral hypoglycemic agents used today to treat type 2 diabetes mellitus. In this study, biguanide, metformin, and phenformin, all biguanides, were coordinated to oxovanadium(IV) to form potential insulin-enhancing compounds. Highly colored, air-stable, bis(biguanidato)oxovanadium(IV), [VO(big)(2)], bis(N{\textquoteright},N{\textquoteright}-dimethylbiguanidato)oxovanadium(IV) [VO(metf)(2)], and bis(beta-phenethyl-biguanidato)oxovanadium(IV), [VO(phenf)(2)], were prepared. Solvation with dimethylsulfoxide occurred with VO(metf)(2) to form a six-coordinate complex. Precursor ligands and oxovanadium(IV) coordination complexes were characterized by infrared spectroscopy, mass spectrometry, elemental analyses, magnetic susceptibility, and, where appropriate, H-1 NMR spectroscopy. Biological testing with VO(metf)(2), a representative compound, for insulin-enhancing potential included acute (72 h) administration, both by intraperitoneal (i.p.) injection and by oral gavage (p.o,) in streptozotocin (STZ)-diabetic rats. VO(metf)(2) administration resulted in significant blood-glucose lowering at doses of 0.12 mmol kg(-1) i.p. and 0.60 mmol kg(-1) p.o. (previously established as ED50 doses for organically chelated oxovanadium(IV) complexes); however, no positive associative effects due to the presence of biguanide in the complex were apparent. (C) 1999 Elsevier Science Inc. All rights reserved.},
	keywords = {biguanide, BIS(MALTOLATO)OXOVANADIUM(IV), BMOV, coordination complex, GLUCOSE-LOWERING PROPERTIES, insulin mimic, MECHANISM, METFORMIN, MIMETIC AGENT, MUSCLE, RATS, VANADIUM},
	isbn = {0162-0134},
	url = {<Go to ISI>://000084097800010},
	author = {Woo, L. C. Y. and Yuen, V. G. and Thompson, K. H. and McNeill, J. H. and Orvig, Chris}
}
@article {4199,
	title = {Active oxygen species formation in synaptosomes exposed to an aluminum chelator},
	journal = {Neurotoxicology and Teratology},
	volume = {20},
	number = {3},
	year = {1998},
	note = {ISI Document Delivery No.: ZU241Times Cited: 4Cited Reference Count: 37},
	month = {May-Jun},
	pages = {317-320},
	type = {Article},
	abstract = {This study evaluates the potential of two chelators, 1,2-dimethyl-3-hydroxypyridine-4-one (Hdpp) and 1-n-butyl-2-methyl-3-hydroxypyridin-4-one (Hnbp), to modulate cerebral rates of free radical production. The fluorometric assay for 2{\textquoteright},7{\textquoteright}-dichlorofluorescein, which is formed by oxidation of a nonfluorescent precursor (2{\textquoteright},7{\textquoteright}-dichlorofluorescin diacetate), was used to assay reactive oxygen species (ROS) production. The chelator Hdpp alone and the aluminum complexes of each chelator, Al(dpp)(3) and Al(nbp)(3), all inhibited basal rates of generation of ROS within a rat cerebral synaptosomal fraction. In the presence of an iron salt (1 mu M FeSO4), a major enhancement of syn aptosomal ROS formation was apparent. However, with the addition of an equimolar concentration of Hdpp, Al(dpp)(3), or Al(nbp)(3), this stimulation was completely abolished. The N-substituted-3-hydroxy-4-pyridinones have been proposed to be of clinical utility for the removal of iron or aluminum from tissues. The clinical potential of this class of chelator may be enhanced by their ability to inhibit iron-related oxidative events. (C) 1998 Elsevier Science Inc.},
	keywords = {3-HYDROXY-4-PYRIDINONES, aluminum, ALZHEIMERS-DISEASE, CHELATOR, COMPLEXES, DEFEROXAMINE, DESFERRIOXAMINE, Free Radicals, hydroxypyridinones, iron, LIPID-PEROXIDATION, metal chelation, NEUROFIBRILLARY TANGLES, QUANTITATION, RATS, reactive oxygen species},
	isbn = {0892-0362},
	url = {<Go to ISI>://000074176500011},
	author = {Bondy, S. C. and Tseng, H. and Orvig, Chris}
}
@article {4168,
	title = {Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats},
	journal = {American Journal of Physiology-Endocrinology and Metabolism},
	volume = {272},
	number = {1},
	year = {1997},
	note = {ISI Document Delivery No.: WG568Times Cited: 14Cited Reference Count: 39},
	month = {Jan},
	pages = {E30-E35},
	type = {Article},
	abstract = {In association with the insulin-mimetic properties, vanadium and related compounds have been shown to normalize hyperphagia associated with diabetes mellitus. The objective of this study was to clarify the effects of an organic vanadium compound, bis(maltolato)oxovanadium(IV) (BMOV), vs. food restriction on the metabolic abnormalities that occur in diabetes. BMOV was administered daily in drinking water to streptozotocin (STZ)-diabetic rats for 6 wk. Pair-fed groups were fed based on the intake for their respective counterparts from the previous day. Plasma parameters mere measured weekly after a carefully controlled 5-h fasting period. BMOV reduced plasma glucose (diabetic = 31.2 +/- 1.9, diabetic treated = 10.2 +/- 1.8, and diabetic pair fed = 34.2 +/- 1.1 mM), triglyceride, and cholesterol levels to normal without a concomitant increase in plasma insulin levels. There was no body weight gain in the diabetic pair-fed group compared with all other groups. BMOV but not pair feeding was effective in preventing the decreased cardiac function observed in STZ-diabetic rats. These data suggest that the glucose-lowering properties of BMOV are independent of the effects of dietary restriction and reinforce the efficacy of BMOV as an effective antihyperglycemic agent.},
	keywords = {diabetes, FA/FA, GLUCOSE-HOMEOSTASIS, glucose-lowering effect, HYPERINSULINEMIA, IN-VIVO, INSULIN SENSITIVITY, LONG-TERM IMPROVEMENT, MELLITUS, ORAL VANADATE, RATS, SPONTANEOUSLY HYPERTENSIVE RATS, STREPTOZOTOCIN, SULFATE, VANADYL},
	isbn = {0193-1849},
	url = {<Go to ISI>://A1997WG56800005},
	author = {Yuen, V. G. and Orvig, Chris and McNeill, J. H.}
}
@article {3447,
	title = {Increased potency of vanadium using organic ligands},
	journal = {Molecular and Cellular Biochemistry},
	volume = {153},
	number = {1-2},
	year = {1995},
	note = {ISI Document Delivery No.: TM620Times Cited: 45Cited Reference Count: 46Vanadium SymposiumJUL 29-31, 1994MONTREAL, CANADACanadian Diabet Assoc, Fonds Rech Sante Quebec, Juvenile Diabet Fdn Canada, Marion Merrell Dow Canada, McGill Univ, Med Res Council Canada, Medisense Canada Inc, Merck Frosst, Canada Inc, Miles Canada Inc},
	month = {Dec},
	pages = {175-180},
	type = {Proceedings Paper},
	abstract = {The in vivo glucose lowering effect of orally administered inorganic vanadium compounds in diabetes was first reported in our laboratory in 1985. While both vanadate and vanadyl forms of vanadium are orally active, they are still not well absorbed. We have synthesized several organic vanadium compounds and one compound, bis(maltolato)oxovanadium(lv) or BMOV, has been extensively investigated. BMOV proved effective in lowering plasma glucose and lipids in STZ-diabetic: rats when administered in drinking water over a 25 week period. The maintenance dose (0.18 mmol/kg/day) was approximately 50\% of that required for vanadyl sulfate (VS). Secondary complications of diabetes were prevented by BMOV and no marked toxicity was noted. Oral gavage of STZ-diabetic rats with BMOV also reduced blood glucose levels. The ED(50) for BMOV was 0.5 mmol/kg, while for VS the estimated ED(50) was 0.9 mmol/kg. BMOV was also effective by the intraperitoneal route in STZ-diabetic rats. The ED(50) was 0.08 mmol/kg compared to 0.22 mmol/kg for VS. Some animals treated p.o. or i.p. remained euglycemic for up to 14 weeks. An i.v. infusion of BMOV of 0.05 mmol/kg over a 30 min period reduced plasma glucose levels by 50\% while VS was not effective.},
	keywords = {ADIPOCYTES, BIS(MALTOLATO)OXOVANADIUM(IV), diabetes, DIABETIC, GLUCOSE, HYPERTENSION, IMPROVEMENT, INSULIN ACTION, insulin-mimetic, RATS, RECEPTOR TYROSINE KINASE, resistance, SPONTANEOUSLY HYPERTENSIVE RATS, VANADATE, VANADIUM},
	isbn = {0300-8177},
	url = {<Go to ISI>://A1995TM62000024},
	author = {McNeill, J. H. and Yuen, V. G. and Dai, S. T. and Orvig, Chris}
}
